Key facts
- PreComb’s last known valuation is $10.4M (Dec 2024).
- It has raised $7.8M; the latest was Later Stage VC ($4.0M) in Dec 2024.
- Notable investors include High-Tech Gründerfonds, Kinled Holding, FiveT Capital, Koodos, LongeVC.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for PreComb
- ·The full record, as it builds
Funding rounds
No funding rounds for PreComb are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PreComb
Developer of a 3D drug testing technology designed for vitro cancer diagnosis to improve cancer management. The company's technology is automated microtumor-based profiling, which allows clinical institutions to integrate on-site in the hospital, the test makes it possible to functionally evaluate multiple cancer drugs, drug combinations, and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcomes, enabling physicians to choose effective therapy for cancer treatment for their patients.
- Sector
- Healthcare
- HQ
- Hombrechtikon, Switzerland
- Founded
- 2018
- Employees
- 10
- Website
- precomb.com/
- Ownership
- Privately Held (backing)
PreComb doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PreComb shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PreComb in its N-PORT filings yet. We sweep new filings monthly.